The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Read more about The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Taking on challenging targets: making MYC druggable. Read more about Taking on challenging targets: making MYC druggable.
Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade? Read more about Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade?
Novel therapeutics in hepatocellular carcinoma: how can we make progress? Read more about Novel therapeutics in hepatocellular carcinoma: how can we make progress?
The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Read more about The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.
Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Read more about Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia.
Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint. Read more about Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
Targeting Molecular Aberrations in Breast Cancer: Is It about Time? Read more about Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
